CONTEXT: Mobility limitation is associated with increased morbidity and mortality. The relationship between circulating testosterone and mobility limitation and physical performance is incompletely understood. OBJECTIVE: Our objective was to examine cross-sectional and prospective relations between baseline sex hormones and mobility limitations and physical performance in community-dwelling older men. DESIGN, SETTING, AND PARTICIPANTS: We conducted cross-sectional and longitudinal analyses of 1445 men (mean age 61.0 +/- 9.5 yr) who attended Framingham Offspring Study examinations 7 and 8 (mean 6.6 yr apart). Total testosterone (TT) was measured by liquid chromatography tandem mass spectrometry at examination 7. Cross-sectional and longitudinal analyses of mobility limitation and physical performance were performed with continuous (per SD) and dichotomized [low TT and free testosterone (FT) and high SHBG vs. normal] hormone levels. MAIN OUTCOME MEASURES: Self-reported mobility limitation, subjective health, usual walking speed, and grip strength were assessed at examinations 7 and 8. Short physical performance battery was performed at examination 7. RESULTS: Higher continuous FT was positively associated with short physical performance battery score (beta = 0.13; P = 0.008), usual walking speed (beta = 0.02; P = 0.048), and lower risk of poor subjective health [odds ratio (OR) = 0.72; P = 0.01]. In prospective analysis, 1 SD increase in baseline FT was associated with lower risk of developing mobility limitation (OR = 0.78; 95% confidence interval = 0.62-0.97) and progression of mobility limitation (OR = 0.75; 95% confidence interval = 0.60-0.93). Men with low baseline FT had 57% higher odds of reporting incident mobility limitation (P = 0.03) and 68% higher odds of worsening of mobility limitation (P = 0.007). CONCLUSIONS: Lower levels of baseline FT are associated with a greater risk of incident or worsening mobility limitation in community-dwelling older men. Whether this risk can be reduced with testosterone therapy needs to be determined by randomized trials.
CONTEXT: Mobility limitation is associated with increased morbidity and mortality. The relationship between circulating testosterone and mobility limitation and physical performance is incompletely understood. OBJECTIVE: Our objective was to examine cross-sectional and prospective relations between baseline sex hormones and mobility limitations and physical performance in community-dwelling older men. DESIGN, SETTING, AND PARTICIPANTS: We conducted cross-sectional and longitudinal analyses of 1445 men (mean age 61.0 +/- 9.5 yr) who attended Framingham Offspring Study examinations 7 and 8 (mean 6.6 yr apart). Total testosterone (TT) was measured by liquid chromatography tandem mass spectrometry at examination 7. Cross-sectional and longitudinal analyses of mobility limitation and physical performance were performed with continuous (per SD) and dichotomized [low TT and free testosterone (FT) and high SHBG vs. normal] hormone levels. MAIN OUTCOME MEASURES: Self-reported mobility limitation, subjective health, usual walking speed, and grip strength were assessed at examinations 7 and 8. Short physical performance battery was performed at examination 7. RESULTS: Higher continuous FT was positively associated with short physical performance battery score (beta = 0.13; P = 0.008), usual walking speed (beta = 0.02; P = 0.048), and lower risk of poor subjective health [odds ratio (OR) = 0.72; P = 0.01]. In prospective analysis, 1 SD increase in baseline FT was associated with lower risk of developing mobility limitation (OR = 0.78; 95% confidence interval = 0.62-0.97) and progression of mobility limitation (OR = 0.75; 95% confidence interval = 0.60-0.93). Men with low baseline FT had 57% higher odds of reporting incident mobility limitation (P = 0.03) and 68% higher odds of worsening of mobility limitation (P = 0.007). CONCLUSIONS: Lower levels of baseline FT are associated with a greater risk of incident or worsening mobility limitation in community-dwelling older men. Whether this risk can be reduced with testosterone therapy needs to be determined by randomized trials.
Authors: S Bhasin; T W Storer; M Javanbakht; N Berman; K E Yarasheski; J Phillips; M Dike; I Sinha-Hikim; R Shen; R D Hays; G Beall Journal: JAMA Date: 2000-02-09 Impact factor: 56.272
Authors: Majon Muller; Isolde den Tonkelaar; Jos H H Thijssen; Diederick E Grobbee; Yvonne T van der Schouw Journal: Eur J Endocrinol Date: 2003-12 Impact factor: 6.664
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Johannes D Veldhuis; Olga P Bondar; Roy B Dyer; Sergey A Trushin; Eric W Klee; Ravinder J Singh; George G Klee Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Shehzad Basaria; Andrea D Coviello; Thomas G Travison; Thomas W Storer; Wildon R Farwell; Alan M Jette; Richard Eder; Sharon Tennstedt; Jagadish Ulloor; Anqi Zhang; Karen Choong; Kishore M Lakshman; Norman A Mazer; Renee Miciek; Joanne Krasnoff; Ayan Elmi; Philip E Knapp; Brad Brooks; Erica Appleman; Sheetal Aggarwal; Geeta Bhasin; Leif Hede-Brierley; Ashmeet Bhatia; Lauren Collins; Nathan LeBrasseur; Louis D Fiore; Shalender Bhasin Journal: N Engl J Med Date: 2010-06-30 Impact factor: 91.245
Authors: Monika Eichholzer; Aline Barbir; Shehzad Basaria; Adrian S Dobs; Manning Feinleib; Eliseo Guallar; Andy Menke; William G Nelson; Nader Rifai; Elizabeth A Platz; Sabine Rohrmann Journal: Aging Male Date: 2012-07-23 Impact factor: 5.892
Authors: Grace Huang; Shehzad Basaria; Thomas G Travison; Matthew H Ho; Maithili Davda; Norman A Mazer; Renee Miciek; Philip E Knapp; Anqi Zhang; Lauren Collins; Monica Ursino; Erica Appleman; Connie Dzekov; Helene Stroh; Miranda Ouellette; Tyler Rundell; Merilyn Baby; Narender N Bhatia; Omid Khorram; Theodore Friedman; Thomas W Storer; Shalender Bhasin Journal: Menopause Date: 2014-06 Impact factor: 2.953